|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2002, Vol. 100, No. 3, pp. 791-798
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Myelodysplastic syndrome is not merely "preleukemia"
Maher Albitar,
Taghi Manshouri,
Yu Shen,
Diane Liu,
Miloslav Beran,
Hagop M. Kantarjian,
Anna Rogers,
Iman Jilani,
Chung Wu Lin,
Sherry Pierce,
Emil J. Freireich, and
Elihu H. Estey
From the Departments of Hematopathology, Biostatistics,
and Leukemia, The University of Texas MD Anderson Cancer Center,
Houston.
Myelodysplastic syndrome (MDS) is a disease characterized by
ineffective hematopoiesis. There are significant biologic and clinical
differences between MDS and acute myeloid leukemia (AML). We studied a
cohort of 802 patients, 279 (35%) with newly diagnosed MDS and 523 (65%) with newly diagnosed AML, and compared clinical and biologic
characteristics of the 2 groups. Complete clinical and cytogenetic data
were available on all patients, and a subgroup of patients was studied
for apoptosis, angiogenesis, proliferation, and growth factors. Our
results demonstrate that MDS is a discrete entity that is different
from AML and is characterized primarily by increased apoptosis in early
and mature hematopoietic cells. Using cell sorting and loss of
heterozygosity, we demonstrate that the leukemic cells from MDS
patients are capable of differentiation into mature myeloid cells and
monocytes. We also demonstrate that there is a significant overlap
between AML and MDS when MDS is defined on the basis of an arbitrary
percentage of blasts of 20% or 30%. These data suggest that despite
similarities between AML and MDS in their responses to treatment and
outcomes, MDS is biologically and clinically different from AML and
should not be considered an early phase of AML. The data indicate that
MDS must be better defined on the basis of its biology rather than the
percentage of blasts; further, the data suggest that there is a need to
develop therapeutic approaches that specifically address the biologic abnormalities of MDS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Novotna, R. Neuwirtova, M. Siskova, and Y. Bagryantseva
DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts
Hum. Mol. Genet.,
July 15, 2008;
17(14):
2144 - 2149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Rizzieri, E. Feldman, J. F. DiPersio, N. Gabrail, W. Stock, R. Strair, V. M. Rivera, M. Albitar, C. L. Bedrosian, and F. J. Giles
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res.,
May 1, 2008;
14(9):
2756 - 2762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Estey
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
J. Clin. Oncol.,
May 10, 2007;
25(14):
1908 - 1915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sternberg, S. Killick, T. Littlewood, C. Hatton, A. Peniket, T. Seidl, S. Soneji, J. Leach, D. Bowen, C. Chapman, et al.
Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome
Blood,
November 1, 2005;
106(9):
2982 - 2991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rogers, Y. Joe, T. Manshouri, A. Dey, I. Jilani, F. Giles, E. Estey, E. Freireich, M. Keating, H. Kantarjian, et al.
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia
Blood,
April 1, 2004;
103(7):
2799 - 2801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Donato, J. Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B. Aggarwal, S. Shishodin, M. Albitar, K. Hayes, H. Kantarjian, et al.
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Res.,
January 15, 2004;
64(2):
672 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Amin, I. Jilani, E. H. Estey, M. J. Keating, A. L. Dey, T. Manshouri, H. M. Kantarjian, Z. Estrov, J. E. Cortes, D. A. Thomas, et al.
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
Blood,
September 1, 2003;
102(5):
1866 - 1868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. T. Stopeck, L. R. Silverman, J. E. Lancet, M. A. Cooper, A. L. Hannah, J. M. Cherrington, A.-M. O'Farrell, H. A. Yuen, S. G. Louie, et al.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Blood,
August 1, 2003;
102(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology,
January 1, 2002;
2002(1):
73 - 110.
[Abstract]
[Full Text]
|
|
|
|
|
